GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » StageZero Life Sciences Ltd (TSX:SZLS) » Definitions » Net Income (Discontinued Operations)

StageZero Life Sciences (TSX:SZLS) Net Income (Discontinued Operations) : C$0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2001. Start your Free Trial

What is StageZero Life Sciences Net Income (Discontinued Operations)?

Net Income (Discontinued Operations) indicates the net income that a firm brought in from operations that will not be used in future reporting periods. StageZero Life Sciences's Net Income (Discontinued Operations) for the three months ended in Mar. 2024 was C$0.00 Mil. Its Net Income (Discontinued Operations) for the trailing twelve months (TTM) ended in Mar. 2024 was C$0.00 Mil.

StageZero Life Sciences Net Income (Discontinued Operations) Historical Data

The historical data trend for StageZero Life Sciences's Net Income (Discontinued Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

StageZero Life Sciences Net Income (Discontinued Operations) Chart

StageZero Life Sciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Income (Discontinued Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

StageZero Life Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Mar24
Net Income (Discontinued Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

StageZero Life Sciences Net Income (Discontinued Operations) Calculation

Net Income (Discontinued Operations) indicates the net income that a firm brought in from operations that will not be used in future reporting periods.

Net Income (Discontinued Operations) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

StageZero Life Sciences Net Income (Discontinued Operations) Related Terms

Thank you for viewing the detailed overview of StageZero Life Sciences's Net Income (Discontinued Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

StageZero Life Sciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » StageZero Life Sciences Ltd (TSX:SZLS) » Definitions » Net Income (Discontinued Operations)
Comparable Companies
NSTM RNVA IDTA ISPC FUNI CNTGF DMTKQ NDRA MEDVF IDXG TMO DHR XSWX:LONN IQV A IDXX MTD ICLR ILMN WAT
Traded in Other Exchanges
SZLSF:USA
Address
70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2
Website
https://www.stagezerolifesciences.com
StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.
Executives
James Howard-tripp Director, Senior Officer

StageZero Life Sciences Headlines

No Headlines